Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.60 |
| ▸ | PPARG | P37231 | 17/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502061 | 0.88 | PPARA (0.58) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL5434581 | 0.81 | PTPN1 (0.51) | PPARAPPARGCYP2C9KCNH2PTPN1 | |
| SCHEMBL389034 | 0.79 | TSHR (0.55) | PPARAPPARG | |
| SCHEMBL13717804 | 0.79 | PPARA (0.91) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL5425728 | 0.78 | PPARA (0.47) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL5425774 | 0.77 | LPAR1 (0.59) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL10184533 | 0.76 | PPARA (0.55) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13718167 | 0.76 | PPARA (0.85) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL13899431 | 0.76 | PPARA (0.61) | PPARAPPARGCYP2C9KCNH2 | |
| SCHEMBL31503969 | 0.75 | PPARA (0.48) | PPARAPPARGCYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | PPARA 990/4885PPARG 615/4885CYP2C9 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.